Arcturus Therapeutics Holdings Net Income
| ARCT Stock | USD 7.53 0.04 0.53% |
As of the 11th of February 2026, Arcturus Therapeutics shows the mean deviation of 2.99, and Risk Adjusted Performance of (0.03). Arcturus Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Arcturus Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.6999 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -72.8 M | -69.2 M | |
| Net Loss | -72.8 M | -69.2 M | |
| Net Income Applicable To Common Shares | 8.4 M | 8.8 M | |
| Net Loss | (2.70) | (2.83) | |
| Net Income Per E B T | 1.15 | 1.09 |
Arcturus | Net Income | Build AI portfolio with Arcturus Stock |
The evolution of Net Income for Arcturus Therapeutics Holdings provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Arcturus Therapeutics compares to historical norms and industry peers.
Latest Arcturus Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Arcturus Therapeutics Holdings over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Arcturus Therapeutics financial statement analysis. It represents the amount of money remaining after all of Arcturus Therapeutics Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Arcturus Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcturus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (80.94 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Arcturus Net Income Regression Statistics
| Arithmetic Mean | (39,690,556) | |
| Geometric Mean | 21,404,462 | |
| Coefficient Of Variation | (127.54) | |
| Mean Deviation | 35,336,668 | |
| Median | (24,603,000) | |
| Standard Deviation | 50,621,917 | |
| Sample Variance | 2562.6T | |
| Range | 213M | |
| R-Value | (0.51) | |
| Mean Square Error | 2032.7T | |
| R-Squared | 0.26 | |
| Significance | 0.04 | |
| Slope | (5,075,512) | |
| Total Sum of Squares | 41001.3T |
Arcturus Net Income History
Other Fundumenentals of Arcturus Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Arcturus Therapeutics Net Income component correlations
Arcturus Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Arcturus Therapeutics is extremely important. It helps to project a fair market value of Arcturus Stock properly, considering its historical fundamentals such as Net Income. Since Arcturus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arcturus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arcturus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Arcturus introduce new products? Factors like these will boost the valuation of Arcturus Therapeutics. If investors know Arcturus will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Arcturus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.47) | Revenue Per Share | Quarterly Revenue Growth (0.59) | Return On Assets | Return On Equity |
Understanding Arcturus Therapeutics requires distinguishing between market price and book value, where the latter reflects Arcturus's accounting equity. The concept of intrinsic value - what Arcturus Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Arcturus Therapeutics' price substantially above or below its fundamental value.
Understanding that Arcturus Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Arcturus Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Arcturus Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Arcturus Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Arcturus Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Arcturus Therapeutics.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Arcturus Therapeutics on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Arcturus Therapeutics Holdings or generate 0.0% return on investment in Arcturus Therapeutics over 90 days. Arcturus Therapeutics is related to or competes with Sagimet Biosciences, Humacyte, Voyager Therapeutics, Entrada Therapeutics, Vanda Pharmaceuticals, Achieve Life, and Foghorn Therapeutics. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, an... More
Arcturus Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Arcturus Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Arcturus Therapeutics Holdings upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 15.98 | |||
| Value At Risk | (6.44) | |||
| Potential Upside | 6.53 |
Arcturus Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arcturus Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Arcturus Therapeutics' standard deviation. In reality, there are many statistical measures that can use Arcturus Therapeutics historical prices to predict the future Arcturus Therapeutics' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.27) | |||
| Total Risk Alpha | (0.60) | |||
| Treynor Ratio | (0.22) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arcturus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Arcturus Therapeutics February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.21) | |||
| Mean Deviation | 2.99 | |||
| Coefficient Of Variation | (2,139) | |||
| Standard Deviation | 3.91 | |||
| Variance | 15.31 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.27) | |||
| Total Risk Alpha | (0.60) | |||
| Treynor Ratio | (0.22) | |||
| Maximum Drawdown | 15.98 | |||
| Value At Risk | (6.44) | |||
| Potential Upside | 6.53 | |||
| Skewness | 0.3029 | |||
| Kurtosis | 0.3862 |
Arcturus Therapeutics Backtested Returns
Currently, Arcturus Therapeutics Holdings is somewhat reliable. Arcturus Therapeutics secures Sharpe Ratio (or Efficiency) of close to zero, which signifies that the company had a close to zero % return per unit of standard deviation over the last 3 months. We have found twenty-three technical indicators for Arcturus Therapeutics Holdings, which you can use to evaluate the volatility of the firm. Please confirm Arcturus Therapeutics' risk adjusted performance of (0.03), and Mean Deviation of 2.99 to double-check if the risk estimate we provide is consistent with the expected return of 0.021%. The firm shows a Beta (market volatility) of 0.87, which signifies possible diversification benefits within a given portfolio. Arcturus Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Arcturus Therapeutics is expected to follow. Arcturus Therapeutics right now shows a risk of 3.87%. Please confirm Arcturus Therapeutics potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if Arcturus Therapeutics will be following its price patterns.
Auto-correlation | 0.06 |
Virtually no predictability
Arcturus Therapeutics Holdings has virtually no predictability. Overlapping area represents the amount of predictability between Arcturus Therapeutics time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Arcturus Therapeutics price movement. The serial correlation of 0.06 indicates that barely 6.0% of current Arcturus Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.06 | |
| Spearman Rank Test | 0.21 | |
| Residual Average | 0.0 | |
| Price Variance | 0.24 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Arcturus Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Arcturus Therapeutics Holdings reported net income of (80.94 Million). This is 123.72% lower than that of the Biotechnology sector and 215.55% lower than that of the Health Care industry. The net income for all United States stocks is 114.18% higher than that of the company.
Arcturus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcturus Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcturus Therapeutics could also be used in its relative valuation, which is a method of valuing Arcturus Therapeutics by comparing valuation metrics of similar companies.Arcturus Therapeutics is currently under evaluation in net income category among its peers.
Arcturus Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arcturus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arcturus Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Arcturus Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Arcturus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Arcturus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arcturus Therapeutics' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 606.3 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 603.6 K | Dimensional Fund Advisors, Inc. | 2025-06-30 | 582.3 K | Jacobs Levy Equity Management, Inc. | 2025-06-30 | 495.3 K | Bank Of America Corp | 2025-06-30 | 292.4 K | Empire Life Investments Inc | 2025-06-30 | 264 K | Northern Trust Corp | 2025-06-30 | 221 K | Jpmorgan Chase & Co | 2025-06-30 | 206.9 K | Charles Schwab Investment Management Inc | 2025-06-30 | 190.1 K | Federated Hermes Inc | 2025-06-30 | 4.7 M | Blackrock Inc | 2025-06-30 | 2.6 M |
Arcturus Fundamentals
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.68) % | ||||
| Operating Margin | (0.96) % | ||||
| Current Valuation | 59.59 M | ||||
| Shares Outstanding | 28.41 M | ||||
| Shares Owned By Insiders | 7.54 % | ||||
| Shares Owned By Institutions | 90.27 % | ||||
| Number Of Shares Shorted | 7.19 M | ||||
| Price To Earning | 119.50 X | ||||
| Price To Book | 0.95 X | ||||
| Price To Sales | 2.20 X | ||||
| Revenue | 138.39 M | ||||
| Gross Profit | (94.39 M) | ||||
| EBITDA | (77.4 M) | ||||
| Net Income | (80.94 M) | ||||
| Cash And Equivalents | 283.49 M | ||||
| Cash Per Share | 10.67 X | ||||
| Total Debt | 28.55 M | ||||
| Debt To Equity | 0.58 % | ||||
| Current Ratio | 3.14 X | ||||
| Book Value Per Share | 8.24 X | ||||
| Cash Flow From Operations | (59.75 M) | ||||
| Short Ratio | 11.98 X | ||||
| Earnings Per Share | (2.47) X | ||||
| Target Price | 33.56 | ||||
| Number Of Employees | 174 | ||||
| Beta | 2.43 | ||||
| Market Capitalization | 215.1 M | ||||
| Total Asset | 344.07 M | ||||
| Retained Earnings | (448.81 M) | ||||
| Working Capital | 240.49 M | ||||
| Current Asset | 54.55 M | ||||
| Current Liabilities | 3.52 M | ||||
| Net Asset | 344.07 M |
About Arcturus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcturus Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcturus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcturus Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.